Skip to content

The potential utility of infliximab as a therapeutic alternative for erythrodermic psoriasis is discussed

This report describes the case of a patient with erythrodermic psoriasis who had failed all previous therapies and been hospitalized numerous times over a 12 year period that responded dramatically to treatment with infliximab. The potential utility of infliximab as a therapeutic alternative for erythrodermic psoriasis is discussed. PDF. Erythrodermic, recalcitrant psoriasis: Clinical resolution with infliximab. F. Rongioletti; M. This report describes the case of a patient with erythrodermic psoriasis who had failed all previous therapies and been hospitalized numerous times over a 12-year period that responded dramatically to treatment with infliximab. The potential utility of infliximab as a therapeutic alternative for erythrodermic psoriasis is discussed. This report describes the case of a patient with erythrodermic psoriasis who had failed all previous therapies and been hospitalized numerous times over a 12-year period that responded dramatically to treatment with infliximab. The potential utility of infliximab as a therapeutic alternative for erythrodermic psoriasis is discussed.

The potential utility of infliximab as a therapeutic alternative for erythrodermic psoriasis is discussed 2PubMed journal article Erythrodermic, recalcitrant psoriasis: clinical resolution with inflixima was found in Unbound MEDLINE. The potential utility of infliximab as a therapeutic alternative for erythrodermic psoriasis is discussed. A therapeutic approach to erythrodermic psoriasis: report of a case and a discussion of therapeutic options. Plaque psoriasis accounts for 90 of all people with psoriasis. Third-line therapy which refers to systemic biological therapies that use molecules designed to block specific molecular steps important in the development of psoriasis, such as the TNF antagonists adalimumab, etanercept and infliximab, and ustekinumab, anti-IL12-23 monoclonal antibody. Discuss treatment options (including no active treatment), likely benefit from treatment, and side-effects; agree a management plan. Fumaric acid esters may be considered as an alternative maintenance therapy in patients who are not suitable for the above agents. This site uses cookies. The clinical features of plaque psoriasis vary due to many factors, including chronicity of disease, size of the lesions, body sites, percentage of body surface area (BSA) involved, symptomatology, such as pruritus, burning, or pain, associated joint disease, and prior therapy. Further details of the pathogenesis of psoriasis are discussed in this supplement by Krueger and Bowcock. Because infliximab is a chimeric antibody, there is the potential for development of neutralising antibodies.

Numerous topical and systemic therapies are available for the treatment of the cutaneous manifestations of psoriasis. Therapeutic approaches to generalized pustular psoriasis and psoriatic arthritis are discussed separately. Alternatives include vitamin D analogs, such as calcipotriene and calcitriol, tar, and topical retinoids (tazarotene). The most common type of psoriasis is chronic plaque psoriasis or psoriasis vulgaris 6. Nevertheless, biological therapy was associated with lower toxicity than the systemic treatments previously used 17. These biological treatments are an alternative to conventional treatments for moderate and severe psoriasis. Individual needs vary widely, and treatment selection must be carefully discussed with the doctor. It may have the potential to cause birth defects during that time. PUVA therapy uses a photosensitizing medication (usually psoralen) in combination with UVA radiation.

Unbound Medline

The potential utility of infliximab as a therapeutic alternative for erythrodermic psoriasis is discussed 3The recommendations were developed after discussion of the relevance of the evidence to children, young people and adults with psoriasis. Any systemic upset such as fever and malaise, which are common in unstable forms of psoriasis such as erythroderma or generalised pustular psoriasis. 9 In people whose psoriasis has not responded satisfactorily to a topical treatment strategy, before changing to an alternative treatment:. Severe erythrodermic psoriasis in a patient with 22q11 deletion syndrome Jan C PreissMedizinische Klinik I Gastroenterologie, Infektiologie, Rheumatologie, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, BerlinMed Klin (Munich) 100:275-8. The potential utility of infliximab as a therapeutic alternative for erythrodermic psoriasis is discussed. J Dermatol 30:344-5; discussion 345. 2003. Psoriatic adolescents deal with a potentially disfiguring and lifelong disease that could permanently impair their psychological development. Systemic agents and biologics are administered to patients with moderate-to-severe plaque psoriasis, pustular psoriasis, or erythrodermic psoriasis. However, in everyday practice, the calculation of these indexes is not routinely performed, and at the same time their utility in a psoriatic population with mild disease is controversial. In that sense, they represent a promising therapeutic alternative for juvenile psoriasis too. Discussion. Inflectra provides an alternative, potentially more affordable treatment option for people suffering from severe, debilitating diseases such as rheumatoid arthritis and inflammatory bowel disease while maintaining comparable quality, efficacy and safety to the reference product– As a result of competition, the large savings expected to be generated with biosimilars can provide an opportunity to improve patient access to life-changing medications. Crohn’s disease, adult and paediatric ulcerative colitis and plaque psoriasis. Many people with heart failure should not take Inflectra; so prior to treatment they should discuss any heart condition with their doctors. Other psoriasis systemic therapies such as acitretin and cyclosporine were not selected because of the concern that hepatotoxic and immunosuppressant activity from these agents could potentiate liver damage by chronic HCV infection. With continuing worsening, alternative therapy was sought. Another case report discussed the successful result of etanercept therapy in a 49-year-old man with generalized psoriatic flareup after liver transplantation for his chronic HCV infection. If all authors have none, check No potential conflicts or relevant financial interests in the box below. Remicade is indicated for treatment of moderate to severe plaque psoriasis in adult patients who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or PUVA (see section 5. In responding patients, the alternative strategies for continued treatment are: Maintenance: Additional infusion of 5 mg/kg at 6 weeks after the initial dose, followed by infusions every 8 weeks or Re-administration: Infusion of 5 mg/kg if signs and symptoms of the disease recur (see ‘Re-administration’ below and section 4. Other uses of therapeutic infectious agents such as live attenuated bacteria (e.g., BCG bladder instillation for the treatment of cancer) could result in clinical infections, including disseminated infections.

Treatment Of Psoriasis

Twenty-two patients improved after exenatide therapy was discontinued, and 15 reports described the event as resolved at the time of the report. Healthcare professionals to be aware of the potential for acute pancreatitis with exenatide and be alert to the signs and symptoms of acute pancreatitis. If pancreatitis is confirmed, exenatide should not be restarted unless an alternative etiology for the pancreatitis is identified.